jueves, 20 de junio de 2013

Patentes: "Sostener" y...no ceder.

Slide: F.Comas: Pharmageddon 2012/El día después

Lo denunció la Comunidad Europea

Ahora lo cuantifican...y sacan conclusiones.

Drug manufacturers have developed various “evergreening” strategies that contribute to increased overall healthcare costs. The study provides further evidence that cost-saving policies encouraging generic medicine prescriptions, which can have substantial savings for healthcare expenditures, may be offset by increased costs from follow-on drugs. A hospital's attempts to minimise its own medication costs can, as an unintended consequence, lead to increased overall community healthcare expenditure through “spillover effects”. (s)

No hay comentarios: